TheTechno Optimist.

Drug design engine and pipelineIsomorphic Labs—Isomorphic Labs describes its drug design engine, reporting double AlphaFold 3's accuracy on a protein-ligand benchmarkIsomorphic Labs—Isomorphic Labs raises $2.1B Series B led by Thrive Capital, largest AI-drug-discovery round to dateDrug design engine and pipelineIsomorphic Labs—Isomorphic Labs in Fundraising Discussions at $40–50 Billion ValuationIsomorphic Labs—Isomorphic Labs reportedly raises $2.1B Series BIsoDDE (Isomorphic Drug Design Engine)Isomorphic Labs—Isomorphic Labs unveils IsoDDE, claiming 2x improvement over AlphaFold 3 at predicting drug binding

IsoDDE (Isomorphic Drug Design Engine)

by Isomorphic LabsGB

AI system predicting drug-protein binding with high accuracy. IsoDDE is trained on binding affinity data and outperforms AlphaFold 3 2x on the hardest predictions.

ProtoStage 2 of 5

Outperforms AlphaFold 3 on drug-protein binding. First human trials expected by end of 2026.

Updated 10 Feb 2026Checked 10 Oct0 updates this week

Milestones

Next · First AI-designed oncology candidate enters clinical trials
  1. IsoDDE system unveiled, outperforms AlphaFold 3 2x on bindingFeb 2026Complete.
  2. Series B funding ($2.1B) announcedMay 2026Complete.
  3. First AI-designed oncology candidate enters clinical trialsTarget Q4 2026Not yet reached.

Most important updates

Upcoming

  1. Q4 2026First AI-designed oncology candidate enters clinical trials (next)
Primer